TOP2A/MCM2, p16INK4a, and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions

Table 6 Cellular biomarkers and oxidative damage and their association to HSIL and cervical cancer development

	LSIL^a	HSIL			CC			HSIL^a	CC
	OR	OR	CI	p	OR	CI	p	OR	OR	CI	p
TOP2A/MCM2	1.0	44.9	16.6–121.4	< 0.001	167.4	43.1–∞	< 0.001	1.0	2.6	0.6–∞	0.183
p16INK4a	1.0	16.2	6.7–38.9	< 0.001	51.3	14.4–∞	< 0.001	1.0	1.9	0.5–∞	0.312
Cyclin E	1.0	13.1	5.8–29.9	< 0.001	78.5	21.7–∞	< 0.001	1.0	3.9	0.9–∞	0.060
Ki-67	1.0	17.7	7.5–41.4	< 0.001	89.0	24.1–∞	< 0.001	1.0	2.4	0.7–∞	0.146
Telomerase	1.0	6.1	2.5–14.6	< 0.001	15.6	4.5–∞	< 0.001	1.0	1.4	0.4–∞	0.562
RI-5	1.0	72.7	21.8–242.2	< 0.001	261	56.5–∞	< 0.001	1.0	2.8	0.7–∞	0.152
RI-4	1.0	55.2	18.1–168.3	< 0.001	203.3	47.3–∞	< 0.001	1.0	3.0	0.8–∞	0.110
RI-3	1.0	79.1	23.7–264.4	< 0.001	246.1	55.8–∞	< 0.001	1.0	2.8	0.7–∞	0.140
RI-2	1.0	61.4	20.0–188.8	< 0.001	200.8	44.1–∞	< 0.001	1.0	2.2	0.6–∞	0.224
ROS	1.0	0.7	0.5–1.0	0.055	0.3	0.2–0.5	0.30	1.0	0.4	0.2–0.7	0.003
8-OHdG	1.0	0.8	0.5–1.2	0.321	1.2	0.7–1.9	0.487	1.0	1.2	0.7–2.1	0.415

LSIL Low-grade squamous intraepithelial lesions, HSIL High-grade squamous intraepithelial lesions, CC Cervical cancer, OR Odds ratio, CI Confidence interval, RI Risk index; RI-5 analysis with TOP2A/MCM2, p16INK4a, cyclin E, Ki-67, and telomerase; RI-4 analysis with TOP2A/MCM2, p16INK4a, cyclin E, and Ki-67; RI-3 analysis with TOP2A/MCM2, p16INK4a, and cyclin E, and RI-2 analysis with TOP2A/MCM2 and p16INK4a OR adjusted by age and HPV infection by oncogenic risk (HPV negative, HR, PHR, LHR, and UHR) ^areference category

ISSN: 1471-2407